Fusion Genomics Corporation

Fusion Genomics Corporation Analysis:

Name: Fusion Genomics Corporation Slogan: Innovating disruptive diagnostics assays based on NGS technology to characterize all infectious diseases. Description: Fusion Genomics, founded in 2013, is a Vancouver-based biotechnology company specializing in molecular diagnostics using Next Generation Sequencing (NGS). The company aims to address the global challenge of idiopathic infections, utilizing proprietary technologies such as the ONETestᵀᴹ platform, which offers rapid pathogen identification from various sources with heightened sensitivity and accuracy at a reduced cost.

Industries: Analytics, Health Care Last Investment: $1.00M grant investment at 09 January 2020 Last Investment Investors: Sunnybrook Research Institute

Fusion Genomics' innovative approach has been validated by international laboratories and various Canadian public health agencies. The company's disruptive DNA and RNA capture technology, UNIPrepᵀᴹ, QUANTUMProbesᵀᴹ, and FusionCloudᵀᴹ, has potential for significant impact on the global economy and public health. With its ongoing advancements in genomic testing for pathogens, the company presents an attractive opportunity for potential investors looking to participate in the advancement of molecular diagnostics. For more information or investment opportunities, interested parties can reach out to [email protected].